Figure 6

(A) Difference of RELM- β levels in (A) BAL fluid of hADSC and hBMSC treated mice compared to control, and serum RELM- β levels (B) between asthma patients and normal control. Repeated OVA challenge significantly decreased the RELM-β level, while both MSC treatments significantly increased the RELM-β level. Also, the serum RELM-β level was significantly lower in asthma patients compared to controls. OVA ovalbumin, PBS phosphate buffer saline, hADSC human adipose-derived stem cell, hBMSC human bone marrow mesenchymal stem cell, RELM-β resistin-like molecule-β.